CA1138775A - Suspension composition of benzocaine - Google Patents
Suspension composition of benzocaineInfo
- Publication number
- CA1138775A CA1138775A CA000330752A CA330752A CA1138775A CA 1138775 A CA1138775 A CA 1138775A CA 000330752 A CA000330752 A CA 000330752A CA 330752 A CA330752 A CA 330752A CA 1138775 A CA1138775 A CA 1138775A
- Authority
- CA
- Canada
- Prior art keywords
- benzocaine
- composition according
- copolymer
- composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A composition containing a therapeutically effective amount of powdered benzocaine suspended in are essentially anhydrous carrier and further containing a copolymer of a vinylpyrrolidone and an alpha-olefin as a crystal growth suppressing agent.
A composition containing a therapeutically effective amount of powdered benzocaine suspended in are essentially anhydrous carrier and further containing a copolymer of a vinylpyrrolidone and an alpha-olefin as a crystal growth suppressing agent.
Description
.3~ 5 A SUSPENSION COMPOSITION OF BENZOCAINE
This invention relates to co~positions containing benzocaine and, more particularly, to compositions of this character in which benzocaine powder is present as a suspension in a vehicle that is essentially anhydrous.
Benzocaine is a well-known topical anesthetic and is widely used because of this property in a variety of pharmaceutical preparations. In many of its uses, it has been found convenient or efficacious to suspend the powdered benzocaine in an anhydrous vehicle. In ths typical preparation, benzocaine in finely powdered form is incorporated as a suspension of a vehicle in which it has at most limited solubility.
It has been found, however, that when products of this character are stored over a period of time, and particularly stored at fluctuating temperatures, the benzocaine which previously existed in powdered form, changes its form becoming large, sharp needlelike crystals.
This behavior of benzocaine is believed to be due to the fact that it has poor temperature dependent solubility in the vehicles in which it is suspended e.g. oils and fats. At elevated temperatures, a part of the benzocaine will dissolve in the oil and, upon cooling, the benzocaine will crystallize out as large needles. On repeated warming/cooling cycles, the amount of benzocaine powder will decrease and the needle crystalline form will increase until practically all the fine powder is con-verted into large, needlelike crystals.
:
, r' ~æ, ~.3~ 5
This invention relates to co~positions containing benzocaine and, more particularly, to compositions of this character in which benzocaine powder is present as a suspension in a vehicle that is essentially anhydrous.
Benzocaine is a well-known topical anesthetic and is widely used because of this property in a variety of pharmaceutical preparations. In many of its uses, it has been found convenient or efficacious to suspend the powdered benzocaine in an anhydrous vehicle. In ths typical preparation, benzocaine in finely powdered form is incorporated as a suspension of a vehicle in which it has at most limited solubility.
It has been found, however, that when products of this character are stored over a period of time, and particularly stored at fluctuating temperatures, the benzocaine which previously existed in powdered form, changes its form becoming large, sharp needlelike crystals.
This behavior of benzocaine is believed to be due to the fact that it has poor temperature dependent solubility in the vehicles in which it is suspended e.g. oils and fats. At elevated temperatures, a part of the benzocaine will dissolve in the oil and, upon cooling, the benzocaine will crystallize out as large needles. On repeated warming/cooling cycles, the amount of benzocaine powder will decrease and the needle crystalline form will increase until practically all the fine powder is con-verted into large, needlelike crystals.
:
, r' ~æ, ~.3~ 5
-2-This represents a decided drawback since this crystal growth gives the product containing the benzo-caine a gritty feel limiting its usefulness in the treat-ment of some conditions e.g. hemorrhoids. In addition, when the benzocaine preparation is packaged in a pressurized aerosol container, the crystal growth of the benzocaine tends to produce a high incidence of valve clogging.
It has now been found that this undesired crystal growth in benzocaine suspension products can be prevented by incorporating in said compositions an effective amount of linear copolymer of a vinylpyrrolidone and a long chain alpha-olefin.
It is accordingly an object of the present inven-tion to provide a powdered benzoc~ine type suspension product in which the tendency for crystal growth of benzocaine on storage, and particularly storage at fluc-tuating temperatures is substantially reduced or minimized.
It is also an object of the present invention to provide a product of the aforesaid type which contains therein as a benzocaine crystal-forming-suppressing agent a linear copolymer of a vinylpyrrolidone and a long_ chain alpha-olefin.
Other and more detailed objects will be apparent from the following description and claims.
2~ Fig. 1 are photomicrographs of samples of the various products after storage under the conditions speci-fied; the dimensions of the marked crystals being indi-cated below Plate.
The linear copolymers of a vinylpyrrolidone and a long chain alpha-olefin that can be employed in the present invention can be described by the following formula:
1.31377S
It has now been found that this undesired crystal growth in benzocaine suspension products can be prevented by incorporating in said compositions an effective amount of linear copolymer of a vinylpyrrolidone and a long chain alpha-olefin.
It is accordingly an object of the present inven-tion to provide a powdered benzoc~ine type suspension product in which the tendency for crystal growth of benzocaine on storage, and particularly storage at fluc-tuating temperatures is substantially reduced or minimized.
It is also an object of the present invention to provide a product of the aforesaid type which contains therein as a benzocaine crystal-forming-suppressing agent a linear copolymer of a vinylpyrrolidone and a long_ chain alpha-olefin.
Other and more detailed objects will be apparent from the following description and claims.
2~ Fig. 1 are photomicrographs of samples of the various products after storage under the conditions speci-fied; the dimensions of the marked crystals being indi-cated below Plate.
The linear copolymers of a vinylpyrrolidone and a long chain alpha-olefin that can be employed in the present invention can be described by the following formula:
1.31377S
-3-(l~tC)--CH--(CtllCll~R~ ~It C~--Cll--(CillCIl,7~R~
)~ \N/ R~ Rr~C~CII~ =o n, ... _ b_o~, -cn.~li- ~_ CH, -Cl~CI ~
L (~1H~CH~B~ ,~ L (Cll~cN~
wherein R5 is se'ected from the group consisting of - hydrogen and a'kyl, of from 1 to about 180 carbon atoms, p is an integer of fr~m 10 to 100, and wherein the m's independently represent a numerical value of 0 to 1;
when m .s zero, R5 is hydrogen; when m is 1, R5 is selected from the group consisting of hydrogen and alkvl of from 1 to about 180 carbon atoms, and wherein at least one of the m's in at least one of the N-vlnyl pyrrolidone .~oieties has the value of 1.
The vinylpyrrolidone-long chain alpha-olefin copolymers that may be employed herein have a wide range of molecular weights (about 7,000 to about 20,000) with various '~ns chain alkyls and with various ratios oi long chain allylation. In physical appearance, they range from liquids to solids. Their solubility characteristics range from mineral oil soluble to water dispersible.
Typlc~l of the vinylpyrrolidone-long chain alpha-olefin copolymers that are usefu' for the present purposes are manufactured by the GAF Corporation ~lnder the trade name o~' Ganex V polymers. At the present time, two grades of Ganex V polymers are commercially available: (1) V-216 i3 a liquid material soluble in oils and/or solvents.
It contains C16 alkyls at about 80% substitution ratio and has an average molecular weight of ',300. T~.e CTFA
adopted name is PVP-Hexadecene Copol~e ; (2) V-220 is a waxy solid with a melting point of 3~-36C and is soluble * Tra~e mark B
-~, .3~77S
)~ \N/ R~ Rr~C~CII~ =o n, ... _ b_o~, -cn.~li- ~_ CH, -Cl~CI ~
L (~1H~CH~B~ ,~ L (Cll~cN~
wherein R5 is se'ected from the group consisting of - hydrogen and a'kyl, of from 1 to about 180 carbon atoms, p is an integer of fr~m 10 to 100, and wherein the m's independently represent a numerical value of 0 to 1;
when m .s zero, R5 is hydrogen; when m is 1, R5 is selected from the group consisting of hydrogen and alkvl of from 1 to about 180 carbon atoms, and wherein at least one of the m's in at least one of the N-vlnyl pyrrolidone .~oieties has the value of 1.
The vinylpyrrolidone-long chain alpha-olefin copolymers that may be employed herein have a wide range of molecular weights (about 7,000 to about 20,000) with various '~ns chain alkyls and with various ratios oi long chain allylation. In physical appearance, they range from liquids to solids. Their solubility characteristics range from mineral oil soluble to water dispersible.
Typlc~l of the vinylpyrrolidone-long chain alpha-olefin copolymers that are usefu' for the present purposes are manufactured by the GAF Corporation ~lnder the trade name o~' Ganex V polymers. At the present time, two grades of Ganex V polymers are commercially available: (1) V-216 i3 a liquid material soluble in oils and/or solvents.
It contains C16 alkyls at about 80% substitution ratio and has an average molecular weight of ',300. T~.e CTFA
adopted name is PVP-Hexadecene Copol~e ; (2) V-220 is a waxy solid with a melting point of 3~-36C and is soluble * Tra~e mark B
-~, .3~77S
-4-in oils and solvents. It contains C20 alkyls at about 70 - substitution ratio and has an average molecular weight of8,600. The CTFA adopted name is PVP-Eicosene Copolymer (See GAF Corporation Ganex V Polymer Bulletin 1977 and GAF Corporation Ganex V Polymer Preliminary Data Sheet 752-65 including Toxicity Data.
The guantity of the vinylpyrrolidone-long chain alpha-olefin copolymer that will be incorporated in the products of the present invention will, for the most part, depend upon the amount of benzocaine they contain. To achieve crystal growth inhibition, in accordance with this inven-tion, generally the ratio of vinylpyrrolidone long chain alpha-olefin copolymer to benzocaine employed should be in the range of from about 0.05 to 4 parts of copolymer (and preferably 0.2 to 1 part of copolymer~ and 1 part of benzocaine.
The quantity of benzocaine that may be included in the present compositions is not particularly critical.
They should of course contain enough to be therapeutically effective. Ordinarily, the benzocaine concentration will fall in the range of 1% to 30% by weight and preferably 2% to 20% by weight based on the total weight of the compo-sition. The upper level, however, is not limited and it ;~ 25 may be as high as the product can tolerate.
The essentially anhydrous vehicles for the benzo-caine and copolymer that can be employed in the present invention can take a variety of forms. Thus, for example, it might take the form of an organic liquid in which the benzocaine and copolymer are suspended. The quantity of these liquid vehicles in the compositions of this inven-tion may vary somewhat. Ordinarily, however, it will usually constitute from 40.0% to 95% by weight of the t`~
3~7S
total composition.
The types of liquid vehicles that can be used are also quite varied and the particular liquid selected is of no great critical significance. ~ypical among the organic liquids which are useful, alone or in combination, include: hydrocarbon oils e.g. mineral oil, petroleum oils, liquid petrolatums; petroleum solvents; fatty acid - esters e.g. isopropyl myristate, isopropyl palmitate, butyl stearate, glycol dioleate, dioctyl sebacate, etc.;
vegetable oils e.g. coconut oil, peanut oil, soybean oil, linseed oil, etc.; fatty acids e.g. coconut fatty acid, oleic acid, isostearic acid, lauric acid, etc.; fatty alcohols e.g. lauryl alcohol, oleyl alcohol, hexadecyl alcohol, etc.; mixtures of organic liquids e.g. chlorinated hydrocarbons and mineral oil, methyl salicylate, homo menthyl salicylate, etc.; dimethyl silicone fluids (non-~olatile and volatile) and their derivatives.
The liquid vehicles can be modified by the inclusion of liquid or solid additives in order to change their solubility, viscosity or organoleptic characteristics.
The liquid additives can be selected from the group of polyalkylene glycols and their derivatives such as Ucon -fluids: Ucon LB, Ucon 50HB, Ucon 75H [these are reaction products of butyl alcohol and propylene oxide, butyl alcohol and propylene oxide and ethylene oxide (50%/50%), and butyl alcohol and propylene oxide (25%) and ethylene oxide (75%)]; polyalkylene block copolymers of the Poloxamer or Meroxapol type; polyalkylene triols, etc. These addi-tives are good benzocaine solvents but when used in combina-tion with the basic carriers do not dissolve benzocaineand retain it in the suspended form.
The solid additives for inclusion in the liquid carrier include solid waxes, fats or other solid materials, * Trade mark ~3 1~ 3~75 typical of which are petroleum gellies and waxes; cocoa butter; natural and synthetic alkyl glycerides; glycol and polyol alkyl esters or ethers; natural waxes of plant, animal or insect origin and/or their synthetic substitutes;
S polyethylene wax polymers and copolymers; other similar suitable substances.
The quantity of said liquid or solid additives that may be employed in the composition of this in~ention that employ a liquid vehicle will vary depending upon the result that is desired. Ordinarily, when they are employed, they will constitute between about 1% to about 40~ by weight based on the total weight of the composition.
Another component that is advantageously used in the liquid vehicle compositions of this invention is a suitable suspending agent. Typical among the suspending agents which are known in the art and are useful for the - present purposes include: quaternium 18 hectorite, quater-1 nium 18 bentonite and stearalkonium hectorite; polyethylene; based homo polymers and copolymers; micronized and fumed silicas, glyceryl hydroxystearates; aluminum stearates; etc.
The clay type suspending agents require a suitable polar agent such as ethanol, propylene carbonate or a surfactant to promote the gelling.
The quantity of suspending agent utilized may vary somewhat. Usually, however, this will constitute between about 0.25% to about 10% by weight and preferably between about 0.5% to about 4% by weight based on the totai weight of the composition.
Liquid vehicle compositions of this invention can be dispensed as sprays or foams by packaging them in suitable spray pump or aerosol containers. When a foam is chosen, the inclusion of an appropriate foaming agent is desirable.
The formulations dispensed from aerosol containers will ; contain compatible propellants.
~ ,, ` ~ 3~3~7S
Typical foaming agents useful for the compositions of this invention include resinous silicone copolymers which have been described in detail in the U.S. Patent to Leonard Mac~les 3,770,648. Also, the suitable propellant systems have been described in the above cited patent.
The essentially anhydrous carrier of the present invention may also be a solid. In this case, the compo-sition may take the form of an ointment, suppository, anhydrous cream, gel, etc. A typical carrier for an ointment is petrolatum; whereas, for a suppository type ; composition, a typical carrier would be cocoa butter or its substitute. However, it is within the scope of this invention to use any anhydrous cream, ointment, gel or suppository base known in this art as suspension carriers.
The quantity of solid carrier that can be employed will obviously vary widely. Ordinarily, this will constitute between about 40% to 95% by weight based on the total weight of the composition.
As in the case with the liquid vehicle, it is sometimes useful to use a suspending agent when the solid vehicle iq employed. In this ca~e, the suspending agent will comprise from about 0.25% to about 10% by weight ~,~
and preferably from about 0.5% to about 4% by weight based on the total weight of the composition.
The above said compositions can also contain addi-tional adjuncts known in the art to obtain special required properties. This may be the case where the carrier iR a liquid or a solid. By way of example, the following may be mentioned:
1. Surfactants to impart rinsing, spreading and cleansing properties such as polyol esters and diesters, sorbitan esters, polyalkylene sorbitan esters, phosphate esters, polyol ethers, lecithins, alkanolamides, etc.
2. Protectants such as zinc oxide, alumina gel, , 3B~7S
cocoa butter, lanolin and its derivatives, petrolatum, shark liver oil, bismuth subnitrate, etc.
3. Vasoconstrictors such as ephedrine and its salts, phenylephrine and its salts, epinephrine, etc.
4. Anti-inflammatory agents such as derivatives of the corticosteroids, hydrocortisone alcohal or hydro-cortisone acetate, etc.
The guantity of the vinylpyrrolidone-long chain alpha-olefin copolymer that will be incorporated in the products of the present invention will, for the most part, depend upon the amount of benzocaine they contain. To achieve crystal growth inhibition, in accordance with this inven-tion, generally the ratio of vinylpyrrolidone long chain alpha-olefin copolymer to benzocaine employed should be in the range of from about 0.05 to 4 parts of copolymer (and preferably 0.2 to 1 part of copolymer~ and 1 part of benzocaine.
The quantity of benzocaine that may be included in the present compositions is not particularly critical.
They should of course contain enough to be therapeutically effective. Ordinarily, the benzocaine concentration will fall in the range of 1% to 30% by weight and preferably 2% to 20% by weight based on the total weight of the compo-sition. The upper level, however, is not limited and it ;~ 25 may be as high as the product can tolerate.
The essentially anhydrous vehicles for the benzo-caine and copolymer that can be employed in the present invention can take a variety of forms. Thus, for example, it might take the form of an organic liquid in which the benzocaine and copolymer are suspended. The quantity of these liquid vehicles in the compositions of this inven-tion may vary somewhat. Ordinarily, however, it will usually constitute from 40.0% to 95% by weight of the t`~
3~7S
total composition.
The types of liquid vehicles that can be used are also quite varied and the particular liquid selected is of no great critical significance. ~ypical among the organic liquids which are useful, alone or in combination, include: hydrocarbon oils e.g. mineral oil, petroleum oils, liquid petrolatums; petroleum solvents; fatty acid - esters e.g. isopropyl myristate, isopropyl palmitate, butyl stearate, glycol dioleate, dioctyl sebacate, etc.;
vegetable oils e.g. coconut oil, peanut oil, soybean oil, linseed oil, etc.; fatty acids e.g. coconut fatty acid, oleic acid, isostearic acid, lauric acid, etc.; fatty alcohols e.g. lauryl alcohol, oleyl alcohol, hexadecyl alcohol, etc.; mixtures of organic liquids e.g. chlorinated hydrocarbons and mineral oil, methyl salicylate, homo menthyl salicylate, etc.; dimethyl silicone fluids (non-~olatile and volatile) and their derivatives.
The liquid vehicles can be modified by the inclusion of liquid or solid additives in order to change their solubility, viscosity or organoleptic characteristics.
The liquid additives can be selected from the group of polyalkylene glycols and their derivatives such as Ucon -fluids: Ucon LB, Ucon 50HB, Ucon 75H [these are reaction products of butyl alcohol and propylene oxide, butyl alcohol and propylene oxide and ethylene oxide (50%/50%), and butyl alcohol and propylene oxide (25%) and ethylene oxide (75%)]; polyalkylene block copolymers of the Poloxamer or Meroxapol type; polyalkylene triols, etc. These addi-tives are good benzocaine solvents but when used in combina-tion with the basic carriers do not dissolve benzocaineand retain it in the suspended form.
The solid additives for inclusion in the liquid carrier include solid waxes, fats or other solid materials, * Trade mark ~3 1~ 3~75 typical of which are petroleum gellies and waxes; cocoa butter; natural and synthetic alkyl glycerides; glycol and polyol alkyl esters or ethers; natural waxes of plant, animal or insect origin and/or their synthetic substitutes;
S polyethylene wax polymers and copolymers; other similar suitable substances.
The quantity of said liquid or solid additives that may be employed in the composition of this in~ention that employ a liquid vehicle will vary depending upon the result that is desired. Ordinarily, when they are employed, they will constitute between about 1% to about 40~ by weight based on the total weight of the composition.
Another component that is advantageously used in the liquid vehicle compositions of this invention is a suitable suspending agent. Typical among the suspending agents which are known in the art and are useful for the - present purposes include: quaternium 18 hectorite, quater-1 nium 18 bentonite and stearalkonium hectorite; polyethylene; based homo polymers and copolymers; micronized and fumed silicas, glyceryl hydroxystearates; aluminum stearates; etc.
The clay type suspending agents require a suitable polar agent such as ethanol, propylene carbonate or a surfactant to promote the gelling.
The quantity of suspending agent utilized may vary somewhat. Usually, however, this will constitute between about 0.25% to about 10% by weight and preferably between about 0.5% to about 4% by weight based on the totai weight of the composition.
Liquid vehicle compositions of this invention can be dispensed as sprays or foams by packaging them in suitable spray pump or aerosol containers. When a foam is chosen, the inclusion of an appropriate foaming agent is desirable.
The formulations dispensed from aerosol containers will ; contain compatible propellants.
~ ,, ` ~ 3~3~7S
Typical foaming agents useful for the compositions of this invention include resinous silicone copolymers which have been described in detail in the U.S. Patent to Leonard Mac~les 3,770,648. Also, the suitable propellant systems have been described in the above cited patent.
The essentially anhydrous carrier of the present invention may also be a solid. In this case, the compo-sition may take the form of an ointment, suppository, anhydrous cream, gel, etc. A typical carrier for an ointment is petrolatum; whereas, for a suppository type ; composition, a typical carrier would be cocoa butter or its substitute. However, it is within the scope of this invention to use any anhydrous cream, ointment, gel or suppository base known in this art as suspension carriers.
The quantity of solid carrier that can be employed will obviously vary widely. Ordinarily, this will constitute between about 40% to 95% by weight based on the total weight of the composition.
As in the case with the liquid vehicle, it is sometimes useful to use a suspending agent when the solid vehicle iq employed. In this ca~e, the suspending agent will comprise from about 0.25% to about 10% by weight ~,~
and preferably from about 0.5% to about 4% by weight based on the total weight of the composition.
The above said compositions can also contain addi-tional adjuncts known in the art to obtain special required properties. This may be the case where the carrier iR a liquid or a solid. By way of example, the following may be mentioned:
1. Surfactants to impart rinsing, spreading and cleansing properties such as polyol esters and diesters, sorbitan esters, polyalkylene sorbitan esters, phosphate esters, polyol ethers, lecithins, alkanolamides, etc.
2. Protectants such as zinc oxide, alumina gel, , 3B~7S
cocoa butter, lanolin and its derivatives, petrolatum, shark liver oil, bismuth subnitrate, etc.
3. Vasoconstrictors such as ephedrine and its salts, phenylephrine and its salts, epinephrine, etc.
4. Anti-inflammatory agents such as derivatives of the corticosteroids, hydrocortisone alcohal or hydro-cortisone acetate, etc.
5. Counterirritants such as camphor, menthol, resorcinol, eucalyptus oil, etc.
6. Additional local anesthetics such as benzyl alcohol, diperodon hydrochloride, pramoxine hydrochloride, etc.
- 7. Opacifiers such as titanium dioxide, zinc oxide, etc.
8. Antioxidants such as butylated hydroxyanisole, ; butylated hydroxytoluene, alpha-tocopherol and its deriva-tives, ascorbic acid and its derivatives, dialkyl-thio-dipropionates, etc.
9. Preservatives, perfumes and colors.
!~ 20 10. Other additives such as retinol (Vitamin A) and it~ derivatives; collagen, soluble or microcrystalline;
proteins and their hydrolysates; antihistamines such as chlorpheniramine maleate, diphenhydramine hydrochloride, etc.
This invention can be applied to any anhydrous preparation containing benzocaine as a local anesthetic.
In addition to hemorrhoidal products, it can also be applied to burns, s~nburn, poison ivy, insect bite, otic (ear), teething (gums) preparations, etc.
The following Examples are given to further illus-trate this invention. It is to be understood, however, that the invention is not limited thereto.
T~e terms used in the Examples and elsewhere in this application are generally the CTFA designated names 3~77S
listed in the CTFA Cosmetic Ingredient Dictionary, Second ; Edition (1977). However, materials which are listed in the CTFA Dictionary as a group, or which are not listed in the CTFA Dictionary, are given below:
; 5 Cab-O-Sil M-5: Fumed silicon dioxide, 0.012 micron - particle size, manufactured by the Cabot Corporation, Boston, Mass.
- A-C Polyethylene 617: Ethylene homopolymer, softening point of 102C, hardness 8.0 dmm, density 0.91 g/cc, viscosity at 140C 180 cps, manufactured by Allied Chemical Corp., Specialty Chemicals Division.
Thixcin R: Trihydroxystearin, glyceryl tri(12-hydroxystearate), a suspending agent manufactured by the NL Industries, Hightstown, New Jersey.
Silicone CS-4262: 50% solution in isopropyl myristate of resin containing SiO2 units and (CH3)3SiOl/2 units in which the ratio of SiO2 units to (CH3)3SiOl/2 units is 1.33 (or 0.75 to 0.25) having an average M.W.
of 5000 to 8000; hydroxy content of 3 to 5% by weight based on the total weight resin and a viscosity (50%
xylene solution) of 4 to 8 centistokes at 25C, manufac-tured by General Electric, Silicone Products Department. _ Siloxane F-251: A volatile silicone consisting -of a mixture of low molecular weight cyclic dimethyl-polysiloxanes tcyclomethicones) with specific gravity 0.95, viscosity at 25C of 3.1 cs, flash point 80C, boiling point 182C, manufactured by the SWS Silicones Corp., Adrian, Michigan.
Wecobee M: A synthetic triglyceride derived from coconut and palm kernel oils, saponification value 243, melting point 96/80F, viscosity at 150F, 13.5 cp, manufactured by the PVO International Inc.
* Trade mark 31~ f ~5 1- ~ ~ 1'- 0 ~- C (D ~ ~ I P,l ~;
S O O ID N X I
Eit~1--'': O~ it t~ Oco ~~ O rD
3 0Pl ~-- O PJ 1'- t~ ~- OI It N ~ O
O ~ ~ O (D
N ~ o O
f~ 3 1--O 1'- U) ~ 0 3 ~I ~
C P~ q ~D 1'-O D
O O N Ul N 1--' W tl ~ I I I I I I I I ~1--~C !~-I I I I II O O O O I I I O ~ ~
i- ~ ~n .~ o I . . I I . . . . I I I ~ X ~
. I O O I I O ~D O O O I I I O ~ ~
o U~
O. _.
~o CO W ~
O o 1-- I I I I.rl ~ ) 1-- Ul N I I N I ~ X
O I~ O O D O O O O
l_ O ¦ I I I I I I ~1 N ~rl N I ~P I I W
I O O O O O I I lP X
I I I I ~Jl I ~I N N I ~ I I I W
. ~ I Ul X
O ~ O ~ O o ~n -l 1~ ~ N ~1 N I I I l_ W
. O O ~-- CO O O O O
O ~JI ~11 313~75 t O O tD N rt Pl ~ 0 X ~ i O co ~D
~3 0 P~ X Pl P~
X to~ Pl, t~, J, 1 2- 0 rt O ~ u~ C
~ ~S O 1-- otD ~ ~
-: ~ o ~ - ~ o ~ :C
o g O
o 8 ~ o ~3 ~_ ~ C
~D
:' o o ~n o o o ~ o o ~ o O O O U~ O I I ~J ~I I ~D ~I CO ~D ~I X
O O ~ n o ~ ~ o co ~
I_ ~
O ,_.
., o a~ o o o o ~ D O ~ W
O ~ I ~ 0 X X It O 0 2 ~ ~ I O U~ ~ O Ct~ ~ ~ O
O ~1 ~
O ~ O O ~ XI ~ 0 ~ N
O O I ~D O I I ~J ~CO I ~I CO ~ ~O X
,' O o ~ ~n O 1~ oo o co ~ ~ 0~
I_ ~
O ~I
O O) O 1- 0 U~ ~ ~ IJ O ~ Ul O I I I ~I I ~I ~ D O ~
O O ~O ~ Ul a~ o o x O ~ W
O O~ O O O O P CO 1-- ~ 1-- 0 . I I ~ W
O O O ~D O I O `~ X I CO ~I CO ~ X
o o ~ .n o o ~ oo o c~
o a~ i_ O ~ O I-- O ~ o ~ ~ 1-- 1--. . . I ,1 I I-W
O o o ~ o I I ~I o I ~ ~ CO CO ~ X
O O ~D X ~rl O ~) O O CO CD
1~ ,p, O ~ O O O O ~ ~ O 1- I- O
O O O ~D O I O ~ ~n I ~ oo co ~D ~ X
O O ~ n o o co ~ co co ~
..
.3B7'7$
; Ointments Ex. 14 Ex. 15 Petrolatum, whita 74.75 72.50 Lanolin, anhydrous 5.00 5.00 ~enzocaine 15.00 10.00 PVP-Eicosene Copolymer 3.00 5.00 Camphor 2.00 2.25 Eucalyptus Oil 0.25 0.25 Zinc oxide -- 5.00 100.00 100.00 Suppositories Ex. 16 Ex. 17 Cocoa butter 75.00 --Wecobee M -- 72.5 Benzocaine 15.00 10.0 PVP-Eicosene Copolymer 5.00 15.0 Zinc Oxide 5.00 --Camphor -- 2.25 Eucalyptus Oil -- 0.25 100.00 100.00 To test the capability of the linear - vinyl-pyrrolidone-long chain alpha-olefin copolymers described above to suppress benzocaine crystal growth in essentially anhydrous carriers, the following experiments were carried out.
Samples of two compositions were prepared identified as BK 1343-1 and BK 1343-4 having the formulas set forth below:
`` ` ~L~.3~3~7S
% by Wt.
Benzocaine 5.00 Cocoa butter 5.00 Mineral Oil 80/90 SSU 86.00 Quaternium 18 Hectorite 1.00 PEG 8 Dilaurate 2.00 Silicone CS-4262 l.~o 100.00 % by Wt.
Benzocaine 5.00 Cocoa butter 5.00 PVP-Eicosene Copolymer 1.00 Mineral Oil 80/90 SSU 83.95 Quaternium 18 Hectorite 2.00 PEG 8 Dilaurate 2.00 Butylated Hydroxytoluene 0.05 Sili~one CS-4262 1.00 100.00 Samples of the aforesaid compositions were stored under the following conditions:
I. Room temperature for 3 months.
II. 125F for 3 months.
III. 3 Months at 32/125F cycles i.e. stored for at least 24 hours at each of the following temperatures respectively: room temperature, 32F, room temperature~
105F, 125F, 105F and room temperature.
- Microscopic Study Microphotographs were made of samples of Products BK 1343-1 and BK 1343-4 after storage under the conditions ~ , ~-~ * Trade mark - 1~3!377S
described in I, II and III above. These are shown in Figure 1 of the drawings; the dimensions of the crystals being indicated below each Plate. Product BK 1343-1 (that does not contain the vinylpyrrolidone copolymer) shows a significant growth of benzocaine crystals at room temperature; the growth being further enhanced at 125F and 32/125F cycle storage. (See Plates 1, 2 and 3 that show clearly the crystal growth and dimensions of the largest crystal in the field). In contrast, product BK 1343-4 (containing the vinylpyrrolidone copolymer) shows very small benzocaine crystals at room temperature, 125F
and 32/125F cycle storage. In this connection, see Plates 4, 5, and 6.
Valve Clogging Study To evaluate the valve clogging and malfunction characteristics of aerosolized benzocaine suspensions, the following tests were run. The benzocaine suspension formulations were packaged in pressurized aerosol con-tainers and subjected to elevated temperature storage as described above. After storage at constant elevated temperatures, the aerosol cans were transferred to room temperature and then actuated once daily until the cans were evacuated completely. The cans exposed to fluctuating temperature cycles were also actuated when brought to room temperature. It was observed that benzocaine suspen-sions formulated without the vinylpyrrolidone copolymer showed very high incidence of clogging (about 35%). On the other hand, formulations of benzocaine suspensions containing the vinylpyrrolidone copolymer did not show any malfunction. Over 300 aerosol cans representing about 15 various formula modifications were evacuated and no valve clogging was observed.
!~ 20 10. Other additives such as retinol (Vitamin A) and it~ derivatives; collagen, soluble or microcrystalline;
proteins and their hydrolysates; antihistamines such as chlorpheniramine maleate, diphenhydramine hydrochloride, etc.
This invention can be applied to any anhydrous preparation containing benzocaine as a local anesthetic.
In addition to hemorrhoidal products, it can also be applied to burns, s~nburn, poison ivy, insect bite, otic (ear), teething (gums) preparations, etc.
The following Examples are given to further illus-trate this invention. It is to be understood, however, that the invention is not limited thereto.
T~e terms used in the Examples and elsewhere in this application are generally the CTFA designated names 3~77S
listed in the CTFA Cosmetic Ingredient Dictionary, Second ; Edition (1977). However, materials which are listed in the CTFA Dictionary as a group, or which are not listed in the CTFA Dictionary, are given below:
; 5 Cab-O-Sil M-5: Fumed silicon dioxide, 0.012 micron - particle size, manufactured by the Cabot Corporation, Boston, Mass.
- A-C Polyethylene 617: Ethylene homopolymer, softening point of 102C, hardness 8.0 dmm, density 0.91 g/cc, viscosity at 140C 180 cps, manufactured by Allied Chemical Corp., Specialty Chemicals Division.
Thixcin R: Trihydroxystearin, glyceryl tri(12-hydroxystearate), a suspending agent manufactured by the NL Industries, Hightstown, New Jersey.
Silicone CS-4262: 50% solution in isopropyl myristate of resin containing SiO2 units and (CH3)3SiOl/2 units in which the ratio of SiO2 units to (CH3)3SiOl/2 units is 1.33 (or 0.75 to 0.25) having an average M.W.
of 5000 to 8000; hydroxy content of 3 to 5% by weight based on the total weight resin and a viscosity (50%
xylene solution) of 4 to 8 centistokes at 25C, manufac-tured by General Electric, Silicone Products Department. _ Siloxane F-251: A volatile silicone consisting -of a mixture of low molecular weight cyclic dimethyl-polysiloxanes tcyclomethicones) with specific gravity 0.95, viscosity at 25C of 3.1 cs, flash point 80C, boiling point 182C, manufactured by the SWS Silicones Corp., Adrian, Michigan.
Wecobee M: A synthetic triglyceride derived from coconut and palm kernel oils, saponification value 243, melting point 96/80F, viscosity at 150F, 13.5 cp, manufactured by the PVO International Inc.
* Trade mark 31~ f ~5 1- ~ ~ 1'- 0 ~- C (D ~ ~ I P,l ~;
S O O ID N X I
Eit~1--'': O~ it t~ Oco ~~ O rD
3 0Pl ~-- O PJ 1'- t~ ~- OI It N ~ O
O ~ ~ O (D
N ~ o O
f~ 3 1--O 1'- U) ~ 0 3 ~I ~
C P~ q ~D 1'-O D
O O N Ul N 1--' W tl ~ I I I I I I I I ~1--~C !~-I I I I II O O O O I I I O ~ ~
i- ~ ~n .~ o I . . I I . . . . I I I ~ X ~
. I O O I I O ~D O O O I I I O ~ ~
o U~
O. _.
~o CO W ~
O o 1-- I I I I.rl ~ ) 1-- Ul N I I N I ~ X
O I~ O O D O O O O
l_ O ¦ I I I I I I ~1 N ~rl N I ~P I I W
I O O O O O I I lP X
I I I I ~Jl I ~I N N I ~ I I I W
. ~ I Ul X
O ~ O ~ O o ~n -l 1~ ~ N ~1 N I I I l_ W
. O O ~-- CO O O O O
O ~JI ~11 313~75 t O O tD N rt Pl ~ 0 X ~ i O co ~D
~3 0 P~ X Pl P~
X to~ Pl, t~, J, 1 2- 0 rt O ~ u~ C
~ ~S O 1-- otD ~ ~
-: ~ o ~ - ~ o ~ :C
o g O
o 8 ~ o ~3 ~_ ~ C
~D
:' o o ~n o o o ~ o o ~ o O O O U~ O I I ~J ~I I ~D ~I CO ~D ~I X
O O ~ n o ~ ~ o co ~
I_ ~
O ,_.
., o a~ o o o o ~ D O ~ W
O ~ I ~ 0 X X It O 0 2 ~ ~ I O U~ ~ O Ct~ ~ ~ O
O ~1 ~
O ~ O O ~ XI ~ 0 ~ N
O O I ~D O I I ~J ~CO I ~I CO ~ ~O X
,' O o ~ ~n O 1~ oo o co ~ ~ 0~
I_ ~
O ~I
O O) O 1- 0 U~ ~ ~ IJ O ~ Ul O I I I ~I I ~I ~ D O ~
O O ~O ~ Ul a~ o o x O ~ W
O O~ O O O O P CO 1-- ~ 1-- 0 . I I ~ W
O O O ~D O I O `~ X I CO ~I CO ~ X
o o ~ .n o o ~ oo o c~
o a~ i_ O ~ O I-- O ~ o ~ ~ 1-- 1--. . . I ,1 I I-W
O o o ~ o I I ~I o I ~ ~ CO CO ~ X
O O ~D X ~rl O ~) O O CO CD
1~ ,p, O ~ O O O O ~ ~ O 1- I- O
O O O ~D O I O ~ ~n I ~ oo co ~D ~ X
O O ~ n o o co ~ co co ~
..
.3B7'7$
; Ointments Ex. 14 Ex. 15 Petrolatum, whita 74.75 72.50 Lanolin, anhydrous 5.00 5.00 ~enzocaine 15.00 10.00 PVP-Eicosene Copolymer 3.00 5.00 Camphor 2.00 2.25 Eucalyptus Oil 0.25 0.25 Zinc oxide -- 5.00 100.00 100.00 Suppositories Ex. 16 Ex. 17 Cocoa butter 75.00 --Wecobee M -- 72.5 Benzocaine 15.00 10.0 PVP-Eicosene Copolymer 5.00 15.0 Zinc Oxide 5.00 --Camphor -- 2.25 Eucalyptus Oil -- 0.25 100.00 100.00 To test the capability of the linear - vinyl-pyrrolidone-long chain alpha-olefin copolymers described above to suppress benzocaine crystal growth in essentially anhydrous carriers, the following experiments were carried out.
Samples of two compositions were prepared identified as BK 1343-1 and BK 1343-4 having the formulas set forth below:
`` ` ~L~.3~3~7S
% by Wt.
Benzocaine 5.00 Cocoa butter 5.00 Mineral Oil 80/90 SSU 86.00 Quaternium 18 Hectorite 1.00 PEG 8 Dilaurate 2.00 Silicone CS-4262 l.~o 100.00 % by Wt.
Benzocaine 5.00 Cocoa butter 5.00 PVP-Eicosene Copolymer 1.00 Mineral Oil 80/90 SSU 83.95 Quaternium 18 Hectorite 2.00 PEG 8 Dilaurate 2.00 Butylated Hydroxytoluene 0.05 Sili~one CS-4262 1.00 100.00 Samples of the aforesaid compositions were stored under the following conditions:
I. Room temperature for 3 months.
II. 125F for 3 months.
III. 3 Months at 32/125F cycles i.e. stored for at least 24 hours at each of the following temperatures respectively: room temperature, 32F, room temperature~
105F, 125F, 105F and room temperature.
- Microscopic Study Microphotographs were made of samples of Products BK 1343-1 and BK 1343-4 after storage under the conditions ~ , ~-~ * Trade mark - 1~3!377S
described in I, II and III above. These are shown in Figure 1 of the drawings; the dimensions of the crystals being indicated below each Plate. Product BK 1343-1 (that does not contain the vinylpyrrolidone copolymer) shows a significant growth of benzocaine crystals at room temperature; the growth being further enhanced at 125F and 32/125F cycle storage. (See Plates 1, 2 and 3 that show clearly the crystal growth and dimensions of the largest crystal in the field). In contrast, product BK 1343-4 (containing the vinylpyrrolidone copolymer) shows very small benzocaine crystals at room temperature, 125F
and 32/125F cycle storage. In this connection, see Plates 4, 5, and 6.
Valve Clogging Study To evaluate the valve clogging and malfunction characteristics of aerosolized benzocaine suspensions, the following tests were run. The benzocaine suspension formulations were packaged in pressurized aerosol con-tainers and subjected to elevated temperature storage as described above. After storage at constant elevated temperatures, the aerosol cans were transferred to room temperature and then actuated once daily until the cans were evacuated completely. The cans exposed to fluctuating temperature cycles were also actuated when brought to room temperature. It was observed that benzocaine suspen-sions formulated without the vinylpyrrolidone copolymer showed very high incidence of clogging (about 35%). On the other hand, formulations of benzocaine suspensions containing the vinylpyrrolidone copolymer did not show any malfunction. Over 300 aerosol cans representing about 15 various formula modifications were evacuated and no valve clogging was observed.
Claims (19)
1. A composition comprising a therapeutically effective amount of powdered benzocaine suspended in an essentially anhydrous carrier and containing an effective amount of a vinylpyrrolidone and a long chain alpha-olefin copolymer of the formula:
wherein R5 is selected from the group consisting of hydrogen and alkyl, of from 1 to about 180 carbon atoms, p is an integer of from 10 to 100, and wherein the m's independently represent a numerical value of 0 to 1; when m is zero, R5 is hydrogen; when m is 1, R5 is selected from the group consisting of hydrogen and alkyl of from 1 to about 180 carbon atoms, and wherein at least one of the m's in at least one of the N-vinylpyrrolidone moieties has the value of 1;
said copolymer being present in said composition at a concentration which is sufficient to significantly suppress crystal growth of said benzocaine on storage.
wherein R5 is selected from the group consisting of hydrogen and alkyl, of from 1 to about 180 carbon atoms, p is an integer of from 10 to 100, and wherein the m's independently represent a numerical value of 0 to 1; when m is zero, R5 is hydrogen; when m is 1, R5 is selected from the group consisting of hydrogen and alkyl of from 1 to about 180 carbon atoms, and wherein at least one of the m's in at least one of the N-vinylpyrrolidone moieties has the value of 1;
said copolymer being present in said composition at a concentration which is sufficient to significantly suppress crystal growth of said benzocaine on storage.
2. A composition according to Claim 1 in which said carrier is a liquid carrier.
3. A composition according to Claim 2 in which the ratio of the said copolymer to benzocaine present is in the range of from about 0.05 parts to about 4 parts of copolymer to 1 part of benzocaine.
4. A composition according to Claim 3 in which the ratio of the copolymer to benzocaine present is in the range of from about 0.2 parts to about 1 part of copolymer to 1 part of benzocaine.
5. A composition according to Claims 1 through 3 in which the benzocaine is present in the range of from about 1% to about 30% by weight based on the total weight of the composition.
6. A composition according to Claims 1 through 3 in which the benzocaine is present in the range of from about 2% to about 20% by weight based on the total weight of the composition.
7. A composition according to Claim 1 in the form of a foamable liquid.
8. A composition according to Claim 1 in the form of an aerosol product.
9. A composition according to Claim 1 in which said carrier is a solid.
10. A composition according to Claim 9 in which the ratio of copolymer to benzocaine present is in the range of from about 0.05 parts to about 4 parts of copolymer to 1 part of benzocaine.
11. A composition according to Claim 10 in which the ratio of copolymer to benzocaine present is in the range from about 0.2 parts to about 1 part of copolymer to 1 part of benzocaine.
12. A composition according to Claims 10 and 11 in which the benzocaine is present in the range of from about 1% to about 30% by weight based on the total weight of the composition.
13. A composition according to Claims 10 and 11 in which the benzocaine is present in the range of from about 2% to about 20% by weight based on the total weight of the composition.
14. A composition according to Claim 10 in the form of a suppository.
15. A composition according to Claim 10 in the form of an ointment.
16. A composition according to Claim 10 in the form of a gel.
17. A composition according to Claim 10 in the form of an anhydrous cream.
18. A composition according to Claim 4 in which the benzocaine is present in the range of from about 1% to about 30% by weight based on the total weight of the composition.
19. A composition according to Claim 4 in which the benzocaine is present in the range of from about 2% to about 20% by weight based on the total weight of the composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/035,115 US4241048A (en) | 1979-05-01 | 1979-05-01 | Suspension composition of benzocaine |
US035,115 | 1998-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1138775A true CA1138775A (en) | 1983-01-04 |
Family
ID=21880737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000330752A Expired CA1138775A (en) | 1979-05-01 | 1979-06-28 | Suspension composition of benzocaine |
Country Status (2)
Country | Link |
---|---|
US (1) | US4241048A (en) |
CA (1) | CA1138775A (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3517080A1 (en) * | 1985-05-11 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | COMPONENT FOR THERAPEUTIC ACTIVE SUBSTANCE DELIVERY SYSTEMS |
US5446063A (en) * | 1986-10-30 | 1995-08-29 | American Home Products Corporation | Anesthetic compositions |
US4897259A (en) * | 1986-12-04 | 1990-01-30 | Bristol-Myers Company | High oil phase pharmaceutical vehicles and sunscreen compositions having waterproof sun protection factors |
US4810489A (en) * | 1986-12-04 | 1989-03-07 | Bristol-Myers Company | High oil phase pharmaceutical vehicles and sunscreen compositions having waterproof sun protection factors |
US4877781A (en) * | 1987-09-30 | 1989-10-31 | Peter G. LaHaye | Medical dispenser and preparation for inflamed tissue |
US5143717A (en) * | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
DE3815221C2 (en) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
US5032400A (en) * | 1989-11-02 | 1991-07-16 | Erie Laboratories | Shark liver oil and garlic oil topical analgesic |
GB9103302D0 (en) * | 1991-02-16 | 1991-04-03 | Smithkline Beecham Plc | Pharmaceutical formulations |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
NZ246421A (en) | 1991-12-18 | 1996-05-28 | Minnesota Mining & Mfg | Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant |
US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
US6180127B1 (en) * | 1992-06-16 | 2001-01-30 | Aquasource, Inc. | Slow release insect repellents |
DE4422881A1 (en) * | 1993-10-25 | 1995-04-27 | Bayer Ag | Colloidally dispersible drug formulations |
DE19726043C1 (en) * | 1997-06-19 | 1999-03-18 | Pelikan Produktions Ag | Ink for use in inkjet printers |
US6344480B1 (en) * | 1997-10-17 | 2002-02-05 | American Home Products Corporation | Oral analgesic compositions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
US20030049283A1 (en) * | 2001-08-31 | 2003-03-13 | Vandell Victor E. | Scalp desensitizing formulation |
US7582284B2 (en) | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
MXPA05004278A (en) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Cosmetic and pharmaceutical foam. |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
WO2005055921A2 (en) | 2003-12-12 | 2005-06-23 | Eran Eilat | Compositions for treatment of ear disorders and methods of use thereof |
US8940321B2 (en) | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
KR20090129998A (en) | 2007-02-11 | 2009-12-17 | 맵 파마슈티컬스, 인코포레이티드 | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
MX359879B (en) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Topical tetracycline compositions. |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
CN108136224B (en) | 2015-10-22 | 2021-10-15 | 高露洁-棕榄公司 | Oral care compositions |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11344495B2 (en) | 2018-09-04 | 2022-05-31 | Babak Ghalili | Veterinary cannabinoid, menthol and anesthetic compositions and methods |
US10966924B2 (en) | 2018-09-04 | 2021-04-06 | Babak Ghalili | Veterinary cannabinoid, menthol and anesthetic compositions and methods |
WO2020051059A1 (en) * | 2018-09-04 | 2020-03-12 | Babak Ghalili | Veterinary cannabinoid, menthol and anesthetic compositions and methods |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2045125A (en) * | 1935-10-19 | 1936-06-23 | Curtis David | Anesthetic solutions |
US2286718A (en) * | 1935-12-17 | 1942-06-16 | Curtis David | Anesthetic compound and solvent for the same |
US2187597A (en) * | 1937-07-17 | 1940-01-16 | James G Blaso | Anesthetic |
US2187598A (en) * | 1939-04-19 | 1940-01-16 | James G Blaso | Self-spraying anesthetic preparation |
US2628182A (en) * | 1950-05-10 | 1953-02-10 | Mizzy Inc | Benzocaine anesthetic solution |
US2728739A (en) * | 1952-08-22 | 1955-12-27 | Celanese Corp | Polymers of n-acrylylpyrrolidine |
US2801201A (en) * | 1953-04-09 | 1957-07-30 | Lincoln Lab Inc | Burn treatment filling for pressure packaged dispenser |
US3171784A (en) * | 1956-11-09 | 1965-03-02 | Gen Aniline & Film Corp | Copolymer of vinyl pyrrolidone and vinyl acetate as aerosol hair spray |
US3166525A (en) * | 1959-05-11 | 1965-01-19 | Gen Aniline & Film Corp | Copolymers of n-vinyl-2-pyrrolidones and vinyl esters as emulsions or latices |
US3019163A (en) * | 1959-07-13 | 1962-01-30 | Harnist Lucien | Hemorrhoidal composition |
NL271677A (en) * | 1960-11-25 | |||
US3294765A (en) * | 1963-10-02 | 1966-12-27 | Gen Aniline & Film Corp | Ethylidene-bis-3 (nu-vinyl-2-pyrrolidone) and polymers thereof |
DE1230036B (en) * | 1963-11-08 | 1966-12-08 | Hoechst Ag | Use of oil-soluble copolymers as emulsifying and dispersing agents |
US3287272A (en) * | 1964-05-18 | 1966-11-22 | Gen Aniline & Film Corp | Lubricating oil composition |
NL124343C (en) * | 1964-06-05 | |||
US3322624A (en) * | 1964-07-07 | 1967-05-30 | Arnar Stone Lab | Low temperature resistant aerosol anesthetic preparation containing benzocaine |
US3427296A (en) * | 1965-03-26 | 1969-02-11 | Gulf Oil Corp | Preparation of ethylene/vinyl-pyrrolidinone copolymers in the presence of ammonia |
US3437647A (en) * | 1966-02-07 | 1969-04-08 | Gaf Corp | Halogen adducts of alkylated polymers of heterocyclic n-vinyl monomers |
US3577516A (en) * | 1969-12-02 | 1971-05-04 | Nat Patent Dev Corp | Preparation of spray on bandage |
US3624224A (en) * | 1969-12-22 | 1971-11-30 | Schering Corp | Novel first aid products |
US3770648A (en) * | 1971-07-12 | 1973-11-06 | Bristol Myers Co | Anhydrous aerosol foam |
US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
GB1421529A (en) * | 1971-09-29 | 1976-01-21 | Rothmans International Ltd | Polymers |
JPS528795B2 (en) * | 1971-12-30 | 1977-03-11 | ||
US3872023A (en) * | 1972-04-17 | 1975-03-18 | Basf Ag | Microcapsules having walls made of copolymer of methylmethacrylate and acetylacetates of mono(meth) acrylates of aliphatic diols |
US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
US3896033A (en) * | 1972-07-03 | 1975-07-22 | Colgate Palmolive Co | Encapsulated fabric softener |
US3914283A (en) * | 1973-12-10 | 1975-10-21 | Hoffmann La Roche | Polymeric local anesthetic and anti-arrhythmic agents |
DE2456807C3 (en) * | 1974-11-30 | 1981-04-09 | Basf Ag, 6700 Ludwigshafen | Process for the production of polymers of vinylpyrrolidone |
-
1979
- 1979-05-01 US US06/035,115 patent/US4241048A/en not_active Expired - Lifetime
- 1979-06-28 CA CA000330752A patent/CA1138775A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
US4241048A (en) | 1980-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1138775A (en) | Suspension composition of benzocaine | |
US7504090B2 (en) | Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials | |
CA1110171A (en) | Waxy-gelling agent in antiperspirant stick | |
US4280994A (en) | Antiperspirant stick compositions | |
CA2085884C (en) | Pressurized hydrofluorocarbon aerosol compositions | |
US5021238A (en) | Water-based two-phase aerosol hairsprays | |
EP0215903A1 (en) | Exothermic stable foam compositions | |
RU2391963C2 (en) | Antiperspirant aerosol product with treated against corrosion container | |
US3395028A (en) | Wax composition and method for making the same | |
BG98681A (en) | Aerosol composition under pressure | |
EP1103249A1 (en) | Anhydrous deodorant cosmetic composition | |
EP0570085A2 (en) | Antiperspirant aerosol composition with high solids content | |
JPH05221832A (en) | Foam-generating aerosol cosmetic for hair | |
US5223247A (en) | Hair spra composition containing water soluble alkylated PVP copolymers as hair fixative therein | |
AU2019386156A1 (en) | Non-aluminium antiperspirant compositions | |
NO145260B (en) | Antiperspirant PREPARATION. | |
EP0259843A2 (en) | Post-foaming gel with an unsaturated or non-linear dialkanolamide or a monoalkanolamide | |
GB1590864A (en) | Thixotropic filling medium for hard gelatin capsules | |
JP2795351B2 (en) | Aerosol composition for human body | |
RU2185143C2 (en) | Compositions for axillary area | |
US3322624A (en) | Low temperature resistant aerosol anesthetic preparation containing benzocaine | |
JP2772073B2 (en) | Powder aerosol composition | |
RU2190998C2 (en) | Water-free antiperspirant composition | |
JPH0259510A (en) | Pressurized packaging composition for setting hair | |
JP2005154315A (en) | Aerosol-type hair cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |